These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

377 related items for PubMed ID: 25756839

  • 1. In vitro susceptibility testing of amphotericin B for Cryptococcus neoformans variety grubii AFLP1/VNI and Cryptococcus gattii AFLP6/VGII by CLSI and flow cytometry.
    Morales BP, Trilles L, Bertho ÁL, Junior IN, de Oliveira Rde V, Wanke B, Lazéra Mdos S.
    Mycoses; 2015 May; 58(5):273-9. PubMed ID: 25756839
    [Abstract] [Full Text] [Related]

  • 2. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
    Nishikawa MM, Almeida-Paes R, Brito-Santos F, Nascimento CR, Fialho MM, Trilles L, Morales BP, da Silva SA, Santos W, Santos LO, Fortes ST, Cardarelli-Leite P, Lázera MDS.
    Med Mycol; 2019 Oct 01; 57(7):864-873. PubMed ID: 30657975
    [Abstract] [Full Text] [Related]

  • 3. Determination of the minimum inhibitory concentration of Cryptococcus neoformans and Cryptococcus gattii against fluconazole by flow cytometry.
    Morales BP, Junior IN, Trilles L, Bertho AL, Oliveira Rde V, Nishikawa MM, Elias Mdos S, Wanke B, Lazéra Mdos S.
    Med Mycol; 2014 Jan 01; 52(1):90-8. PubMed ID: 23808405
    [Abstract] [Full Text] [Related]

  • 4. Molecular typing and in vitro antifungal susceptibility of Cryptococcus spp from patients in Midwest Brazil.
    Favalessa OC, de Paula DA, Dutra V, Nakazato L, Tadano T, Lazera Mdos S, Wanke B, Trilles L, Walderez Szeszs M, Silva D, Hahn RC.
    J Infect Dev Ctries; 2014 Aug 13; 8(8):1037-43. PubMed ID: 25116671
    [Abstract] [Full Text] [Related]

  • 5. In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India.
    Chowdhary A, Randhawa HS, Sundar G, Kathuria S, Prakash A, Khan Z, Sun S, Xu J.
    J Med Microbiol; 2011 Jul 13; 60(Pt 7):961-967. PubMed ID: 21393452
    [Abstract] [Full Text] [Related]

  • 6. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine.
    Espinel-Ingroff A, Chowdhary A, Cuenca-Estrella M, Fothergill A, Fuller J, Hagen F, Govender N, Guarro J, Johnson E, Lass-Flörl C, Lockhart SR, Martins MA, Meis JF, Melhem MS, Ostrosky-Zeichner L, Pelaez T, Pfaller MA, Schell WA, Trilles L, Kidd S, Turnidge J.
    Antimicrob Agents Chemother; 2012 Jun 13; 56(6):3107-13. PubMed ID: 22391546
    [Abstract] [Full Text] [Related]

  • 7. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
    Hagen F, Hare Jensen R, Meis JF, Arendrup MC.
    Mycoses; 2016 Sep 13; 59(9):576-84. PubMed ID: 27061834
    [Abstract] [Full Text] [Related]

  • 8. A flow cytometry method for testing the susceptibility of Cryptococcus spp. to amphotericin B.
    Benaducci T, Matsumoto MT, Sardi JC, Fusco-Almeida AM, Mendes-Giannini MJ.
    Rev Iberoam Micol; 2015 Sep 13; 32(3):159-63. PubMed ID: 25639695
    [Abstract] [Full Text] [Related]

  • 9. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.
    Espinel-Ingroff A, Aller AI, Canton E, Castañón-Olivares LR, Chowdhary A, Cordoba S, Cuenca-Estrella M, Fothergill A, Fuller J, Govender N, Hagen F, Illnait-Zaragozi MT, Johnson E, Kidd S, Lass-Flörl C, Lockhart SR, Martins MA, Meis JF, Melhem MS, Ostrosky-Zeichner L, Pelaez T, Pfaller MA, Schell WA, St-Germain G, Trilles L, Turnidge J.
    Antimicrob Agents Chemother; 2012 Nov 13; 56(11):5898-906. PubMed ID: 22948877
    [Abstract] [Full Text] [Related]

  • 10. Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease.
    Nascimento E, Vitali LH, Kress MRVZ, Martinez R.
    Rev Inst Med Trop Sao Paulo; 2017 Nov 13; 59():e49. PubMed ID: 28793019
    [Abstract] [Full Text] [Related]

  • 11. Correlation of antifungal susceptibility and molecular type within the Cryptococcus neoformans/C. gattii species complex.
    Trilles L, Meyer W, Wanke B, Guarro J, Lazéra M.
    Med Mycol; 2012 Apr 13; 50(3):328-32. PubMed ID: 21859388
    [Abstract] [Full Text] [Related]

  • 12. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
    Tay ST, Tanty Haryanty T, Ng KP, Rohani MY, Hamimah H.
    Mycoses; 2006 Jul 13; 49(4):324-30. PubMed ID: 16784448
    [Abstract] [Full Text] [Related]

  • 13. Molecular types of Cryptococcus neoformans and Cryptococcus gattii in Western Australia and correlation with antifungal susceptibility.
    Lee GA, Arthur I, Merritt A, Leung M.
    Med Mycol; 2019 Nov 01; 57(8):1004-1010. PubMed ID: 30649538
    [Abstract] [Full Text] [Related]

  • 14. Comparative evaluation of Sensititre YeastOne and VITEK 2 against the Clinical and Laboratory Standards Institute M27-E4 reference broth microdilution method for the antifungal susceptibility testing of Cryptococcus neoformans and Cryptococcus gattii.
    Zhang M, Zhou Z, Wang D, Zhou A, Song G, Chen X, Guo J, Wu W.
    Med Mycol; 2022 Mar 04; 60(3):. PubMed ID: 35099022
    [Abstract] [Full Text] [Related]

  • 15. Susceptibility profile of clinical and environmental isolates of Cryptococcus neoformans and Cryptococcus gattii in Uberaba, Minas Gerais, Brazil.
    Andrade-Silva L, Ferreira-Paim K, Mora DJ, Da Silva PR, Andrade AA, Araujo NE, Pedrosa AL, Silva-Vergara ML.
    Med Mycol; 2013 Aug 04; 51(6):635-40. PubMed ID: 23343452
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of antifungal combination against Cryptococcus spp.
    Reichert-Lima F, Busso-Lopes AF, Lyra L, Peron IH, Taguchi H, Mikami Y, Kamei K, Moretti ML, Schreiber AZ.
    Mycoses; 2016 Sep 04; 59(9):585-93. PubMed ID: 27135278
    [Abstract] [Full Text] [Related]

  • 17. Antifungal susceptibility testing with YeastONE™ is not predictive of clinical outcomes of Cryptococcus neoformans var. grubii fungemia.
    Yang JH, Huang PY, Cheng CW, Shie SS, Lin ZF, Yang LY, Lee CH, Wu TS.
    Med Mycol; 2021 Nov 03; 59(11):1114-1121. PubMed ID: 34374784
    [Abstract] [Full Text] [Related]

  • 18. Identification of novel hybrids between Cryptococcus neoformans var. grubii VNI and Cryptococcus gattii VGII.
    Aminnejad M, Diaz M, Arabatzis M, Castañeda E, Lazera M, Velegraki A, Marriott D, Sorrell TC, Meyer W.
    Mycopathologia; 2012 Jun 03; 173(5-6):337-46. PubMed ID: 22081254
    [Abstract] [Full Text] [Related]

  • 19. In vitro synergistic effects of chlorpromazine and sertraline in combination with amphotericin B against Cryptococcus neoformans var. grubii.
    Rossato L, Loreto ÉS, Zanette RA, Chassot F, Santurio JM, Alves SH.
    Folia Microbiol (Praha); 2016 Sep 03; 61(5):399-403. PubMed ID: 26847460
    [Abstract] [Full Text] [Related]

  • 20. Susceptibility to antifungal agents and genotypes of Brazilian clinical and environmental Cryptococcus gattii strains.
    Silva DC, Martins MA, Szeszs MW, Bonfietti LX, Matos D, Melhem MS.
    Diagn Microbiol Infect Dis; 2012 Apr 03; 72(4):332-9. PubMed ID: 22341512
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.